奇正藏藥(002287.SZ)子公司甘南佛閣將臨時停產
格隆匯12月27日丨奇正藏藥(002287.SZ)公佈,根據甘肅省甘南藏族自治州合作市發展和改革局《關於貫徹落實合作市國家重點生態功能區產業准入負面清單的通知》要求,公司全資子公司甘南佛閣藏藥有限公司(“甘南佛閣”)作為醫藥製造業企業,需在2019年12月31日前搬遷至合作市生態產業園,2019年12月31日以後不能在原址繼續生產和發展。
經公司第四屆董事會第十六次會議決議,甘南佛閣於2019年12月31日起臨時停產,不在原址繼續生產和發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.